Taken together, these findings demonstrate the additive effect of LRRK2 on top of underlying polygenic risk of PD and highlights that among LRRK2 G2019S carriers, polygenicity explains some of the variability in whether individuals develop PD. Here, LRRK2 is linked to Parkinson disease.